Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.42 USD | +1.26% | +4.31% | +10.54% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.54% | 845M | |
+4.58% | 109B | |
+11.58% | 105B | |
+0.67% | 22.25B | |
-11.56% | 22.09B | |
-7.63% | 18.68B | |
-38.36% | 17.58B | |
-10.50% | 16.85B | |
+4.61% | 13.76B | |
+36.78% | 12.46B |
- Stock Market
- Equities
- ALXO Stock
- News ALX Oncology Holdings Inc.
- ALX Oncology Doses First Patient in Phase 2/3 Trial of Evorpacept in Gastric, Gastroesophageal Junction Cancer